Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KALV - KalVista Pharmaceuticals, Inc.

12.25
-0.200   -1.633%

Share volume: 403,050
Last Updated: 03-13-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.01%

PREVIOUS CLOSE
CHG
CHG%
$12.45
-0.20
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
49%
Profitability 43%
Dept financing 4%
Liquidity 58%
Performance 65%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.17%
1 Month
25.51%
3 Months
36.87%
6 Months
13.74%
1 Year
-1.45%
2 Year
59.71%
Key data
Stock price
$12.25
P/E Ratio 
0.00
DAY RANGE
$11.96 - $12.57
EPS 
-$2.84
52 WEEK RANGE
$7.30 - $15.50
52 WEEK CHANGE
$2.68
MARKET CAP 
443.823 M
YIELD 
N/A
SHARES OUTSTANDING 
43.082 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.89
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$657,201
AVERAGE 30 VOLUME 
$606,090
Company detail
CEO: T. Andrew Crockett
Region: US
Website: kalvista.com
Employees: 100
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

KalVista Pharmaceuticals, Inc. discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME) products.

Recent news